These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9712059)

  • 21. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
    J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo.
    Yanagi K; Nagayama Y; Nakao K; Saeki A; Matsumoto K; Ichikawa T; Ishikawa H; Hamasaki K; Ishii N; Eguchi K
    Int J Oncol; 2003 Feb; 22(2):345-51. PubMed ID: 12527933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction and inhibition of CD40-CD40 ligand interactions: a new strategy underlying host-virus relationships.
    Sharma MD; Leite de Moraes M; Zavala F; Pontoux C; Papiernik M
    J Immunol; 1998 Nov; 161(10):5357-65. PubMed ID: 9820509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cells require maturation via CD40 to generate protective antitumor immunity.
    Mackey MF; Gunn JR; Maliszewsky C; Kikutani H; Noelle RJ; Barth RJ
    J Immunol; 1998 Sep; 161(5):2094-8. PubMed ID: 9725199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD40-CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii: patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer.
    Subauste CS; Wessendarp M; Sorensen RU; Leiva LE
    J Immunol; 1999 Jun; 162(11):6690-700. PubMed ID: 10352287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Augmentation of in vitro interleukin 10 production after in vivo administration of interleukin 18 is activated macrophage-dependent and is probably not involved in the antitumor effects of interleukin 18.
    Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Ikegami H; Kurimoto M
    Anticancer Res; 1998; 18(6A):4267-74. PubMed ID: 9891477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo.
    Fallarino F; Uyttenhove C; Boon T; Gajewski TF
    J Immunol; 1996 Feb; 156(3):1095-100. PubMed ID: 8557984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production.
    Liu Z; Colpaert S; D'Haens GR; Kasran A; de Boer M; Rutgeerts P; Geboes K; Ceuppens JL
    J Immunol; 1999 Oct; 163(7):4049-57. PubMed ID: 10491009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer.
    Noguchi M; Imaizumi K; Kawabe T; Wakayama H; Horio Y; Sekido Y; Hara T; Hashimoto N; Takahashi M; Shimokata K; Hasegawa Y
    Cancer Gene Ther; 2001 Jun; 8(6):421-9. PubMed ID: 11498762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural killer cell mediated cytotoxicity of tumor cells initiated by neem leaf preparation is associated with CD40-CD40L-mediated endogenous production of interleukin-12.
    Bose A; Baral R
    Hum Immunol; 2007 Oct; 68(10):823-31. PubMed ID: 17961770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional and in situ evidence for nitric oxide production driven by CD40-CD40L interactions in graft-versus-leukemia reactivity.
    Müerköster S; Laman JD; Rocha M; Umansky V; Schirrmacher V
    Clin Cancer Res; 2000 May; 6(5):1988-96. PubMed ID: 10815924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice.
    Stout RD; Suttles J; Xu J; Grewal IS; Flavell RA
    J Immunol; 1996 Jan; 156(1):8-11. PubMed ID: 8598498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD40-CD40 ligand costimulation is required for generating antiviral CD4 T cell responses but is dispensable for CD8 T cell responses.
    Whitmire JK; Flavell RA; Grewal IS; Larsen CP; Pearson TC; Ahmed R
    J Immunol; 1999 Sep; 163(6):3194-201. PubMed ID: 10477587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
    Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
    Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
    J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum.
    Chen L; McGowan P; Ashe S; Johnston JV; Hellström I; Hellström KE
    Cancer Res; 1994 Oct; 54(20):5420-3. PubMed ID: 7522958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand.
    Liu A; Guardino A; Chinsangaram L; Goldstein MJ; Panicali D; Levy R
    Cancer Res; 2007 Jul; 67(14):7037-44. PubMed ID: 17638917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
    Gajewski TF; Fallarino F; Uyttenhove C; Boon T
    J Immunol; 1996 Apr; 156(8):2909-17. PubMed ID: 8609411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo polysaccharide-specific IgG isotype responses to intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7-ligand interactions.
    Wu ZQ; Vos Q; Shen Y; Lees A; Wilson SR; Briles DE; Gause WC; Mond JJ; Snapper CM
    J Immunol; 1999 Jul; 163(2):659-67. PubMed ID: 10395655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.